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Suspecting and Testing for Alpha-1 Antitrypsin
Deficiency—An Allergist’s and/or Immunologist’s
Perspective
Timothy J. Craig, DO Hershey, PaAlpha-1 antitrypsin deﬁciency (AATD) is a hereditary, monogenic
disorder with no unique clinical features. AATD can be difﬁcult to
diagnose as patients commonly present with respiratory symptoms
often mistaken for other respiratory syndromes such as asthma or
smoking-related chronic obstructive pulmonary disease. In
addition, symptoms related to AATDmay also affect other organs,
including the liver, vasculature, and skin. The severity of AATD
varies between individuals, and in severe cases, the irreversible lung
damage can develop into emphysema. Early diagnosis is critical to
enable the implementation of lifestyle changes and therapeutic
options that can slow further deterioration of pulmonary tissue.
OnceAATD is suspected, a range of tests are available (serumalpha-
1 proteinase inhibitor [A1-PI] level measurement, phenotyping,
genotyping, gene sequencing) for conﬁrming AATD. Currently,
intravenous infusion of A1-PI is the only therapy that directly
addresses the underlying cause of AATD, and has demonstrated
efﬁcacy in a recent randomized, placebo-controlled trial. This
review discusses the etiology, testing, and management of AATD
from the allergist’s and/or immunologist’s perspective. It aims to
raise awareness of the condition among physicians who care for
peoplewith obstructive lungdisorders and are therefore likely to see
patients with obstructive lung disease that may, in fact, prove to be
AATD.  2015The Authors. Published by Elsevier Inc. on behalf
of the American Academy of Allergy, Asthma & Immunology. This
is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (J Allergy Clin
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CASE
JT was a 29-year-old man with increasing dyspnea on exer-
tion. His medical history was obtained from his wife. He pre-
sented with dyspnea to an allergist 2 years earlier and was
diagnosed with asthma. His wife recalls his symptoms starting a
few years earlier with dyspnea during exercise. He was treated
with albuterol, as needed, and a combination of a long-acting
beta agonist and inhaled corticosteroid. She remembered him
having intermittent wheezing on his allergist’s exam. He never
had a chest radiograph. His wife remembers his spirometry
demonstrating asthma-like changes, but he never received com-
plete pulmonary function testing or pre- or post-bronchodilator
testing. He smoked less than a pack of cigarettes per day for a
total of 11-pack-year history, but was never informed to stop
smoking. He had no occupational exposures. He had a dog
despite positive skin tests that suggested sensitivity to dogs. His
wife stated that he had no other medical illnesses and had never
experienced any liver disease. After 2 years of therapy, he died
suddenly during sleep. His autopsy demonstrated emphysema.
Autopsy diagnosis was alpha-1 antitrypsin deﬁciency (AATD)
with hypoxia-induced arrhythmia.
ETIOLOGY AND PROGRESSION OF AATD
Elastin is an extracellular protein contributing to the elasticity
of connective tissues and is a major component of the lung.
During inﬂammation, activated neutrophils release various pro-
teolytic enzymes, including neutrophil elastase (NE), to defend
the body against infection. If left unchecked, NE also attacks the
host connective tissue by degrading elastin. AATD is caused by
decreased levels or function of the proteinase inhibitor alpha-1
antitrypsin (AAT; also known as alpha-1 proteinase inhibitor,
A1-PI), which arises as a consequence of mutations in a single
gene (SERPINA1) located on chromosome 14.1 A1-PI is pro-
duced by the liver and plays an important role in the regulation
of NE activity, irreversibly binding NE and targeting it for
degradation. In A1-PI-deﬁcient individuals, insufﬁcient A1-PI
levels lead to uncontrolled NE activity, which results in the
progressive degradation of pulmonary tissue and contributes to
the development of lung disease.2,3 Because this tissue degrada-
tion mainly affects the small airways, especially at the level of the
alveoli, the gas exchange function of the lung can be severely
impaired. Individuals with AATD are often diagnosed with
asthma or chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and/or bronchiectasis, and emphy-
sema, which can become severe.2,4-6 A1-PI is released into the
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A1-PI- Alpha-1 proteinase inhibitor
AATD- Alpha-1 antitrypsin deﬁciency
COPD- Chronic obstructive pulmonary diseaseCT- Computed tomography
FEV1- Forced expiratory volume in one secondIV- Intravenous
NE- Neutrophil elastaseblood and tissues, and evidence suggests that it has multiple
functions (including roles in immunity and inﬂammation)
beyond its antiprotease activity.7 Consequently, AATD symp-
toms are not limited to the lung, and clinical features of the skin
(eg, panniculitis), vasculature (eg, vasculitis), and liver (eg,
cirrhosis) may also occur. In patients with AATD homozygous
for the Z allele (ie, ZZ, see below for a description of the most
common alleles), the abnormal protein accumulates in the liver,
predisposing to hepatitis.1,2,8,9
AATD is a hereditary, autosomal, codominant, monogenic
condition for which more than 500 single nucleotide poly-
morphisms have been identiﬁed, although not all of these have
been validated.3 The most common alleles include:
 M (normal allele)
 Z (leading to low A1-PI levels, associated with severe AATD)
 S (leading to a mild decrease in circulating A1-PI)
 Null allele (no detectable A1-PI synthesis).3
Different allele combinations are associated with various levels
of circulating A1-PI. Individuals with only one defective allele
might not present with clinical features of AATD, and not all
individuals with 2 defective alleles are at the same risk of
developing emphysema (Figure 1).1,4,10-12
The progression of lung disease in individuals with AATD is
slow and symptoms such as cough or wheezing often appear only
within the fourth and/or ﬁfth decade of life, although they
sometimes present earlier, during the second and/or third decade
of life.6 Because AATD leads to irreversible lung damage, it is
crucial to identify patients at risk to enable early diagnosis and
implementation of management and treatment strategies aimed
at reducing the progression of lung disease.
UNDERESTIMATION AND MISDIAGNOSIS OF
AATD
In the USA, the combined prevalence for the A1-PI pheno-
typic classes SS, SZ, and ZZ has been estimated at 1/496.13
Furthermore, 1 in 17 Americans have at least one allele associ-
ated with a degree of risk for AATD (ie, S or Z), and 1 in 6211
Americans are estimated to be homozygous for the Z allele.13
The number of at-risk individuals tested in the USA was re-
ported to have doubled between the years 2007 and 2010,14 but
despite this increase, AATD is still rarely diagnosed. Among the
100,000 individuals in the USA estimated to have AATD, fewer
than 10% have been appropriately diagnosed.15
Respiratory symptoms in people with AATD include cough-
ing, wheezing, excessive sputum production, and dyspnea,
although these symptoms are also common to other respiratory
diseases such as asthma and smoking-related COPD.16 As a
result, AATD is frequently misdiagnosed and this can result in
long delays between the onset of symptoms and obtaining anaccurate diagnosis of AATD. In a recent AATD support group
held at Penn State University, the majority of patients ﬁrst
entered the health care system for their respiratory symptoms
through visits with allergists and were treated for years, often
with immunotherapy, before being referred and found to have
AATD. Previous estimates put the average time from symptom
onset to correct diagnosis of AATD at 7.2 years,17 with
numerous visits to different physicians being involved. A survey
of 304 patients with AATD found that 44% had seen at least 3
physicians before they received an accurate diagnosis of AATD.17
WHEN TO SUSPECT AATD
Although AATD has no unique symptoms, there are clinical
presentations that should raise suspicion (Table I). In particular,
any individual with asthma with incompletely reversible airﬂow
obstruction, as well as patients with COPD, should be tested, as
suggested in a joint statement from the American Thoracic So-
ciety (ATS) and the European Respiratory Society (ERS) in 2003
(summarized in Table II).1 In this statement, various recom-
mendations are also proposed for other individuals, including the
testing of asymptomatic adults with evidence of lung disease and
smoking or occupational exposure, adults with necrotizing pan-
niculitis, children or adults with unexplained liver disease, and
bronchiectasis without apparent etiology. Testing should be
considered for adults and adolescents with a sibling diagnosed to
be homozygous for an AATD deﬁciency allele (eg, ZZ). As
shown in Table II, the joint statement from the ATS/ERS in-
dicates other situations in which testing may be required (eg,
carrier testing) or is not recommended (eg, newborn screening).
To improve the diagnosis of AATD, physicians need to be
aware of the disease, the testing recommendations, and what test
is indicated for their patients. Allergists and/or immunologists, in
particular, may see numerous patients with asthmatic symptoms
and ﬁxed or nonreversible obstruction, which in most cases is
secondary to remodeling, but in some cases may be secondary to
AATD.18 Another population that allergists and/or immunolo-
gists treat is tobacco abusers. Most tobacco-induced respiratory
symptoms in non-AATD patients generally appear at a later age
(ﬁfth decade of life or later), and such symptoms in younger-
than-expected patients should promote further investigations to
check for AATD.19 Other suggestions of AATD include cen-
trilobular and paraseptal emphysema associated with COPD.
Panacinar emphysema may present mainly with basilar changes
on chest radiographs or computed tomography (CT) lung scans;
however, most patients with AATD present with both cen-
trilobular and panlobular emphysema.5
AATD, COPD, and asthma share common signs and symp-
toms, but are different diseases that can be easily differentiated by
quantifying serum A1-PI levels and through phenotypic and/or
genetic testing to identify A1-PI protein and/or SERPINA1 gene
variants, respectively.18
DIAGNOSING AATD
As noted above, certain changes observed by radiography may
suggest AATD. These include basilar predominance of emphy-
sema.5 Characterization of ﬁxed obstructive disease by screening
spirometry is an indication for further testing; in addition,
spirometry should be used to assess the progression of lung
disease. Full pulmonary function tests are expected to demon-
strate obstructive disease, with the increase of residual volume
TABLE I. Common and unique symptoms in AATD, asthma, and
COPD
AATD Asthma COPD
Symptoms onset
Fourth decade Childhood Fifth decade
Airway obstruction
Nonreversible Reversible in
most cases
Nonreversible
Emphysema
Panlobular (panacinar) None Centrilobular/paraseptal
AATD, Alpha-1 antitrypsin deﬁciency; COPD, chronic obstructive pulmonary
disease.
FIGURE 1. Relationships between AATD genotype, A1-PI serum level, and risk of developing emphysema.
1,4,10-12 Depending on their
genotype, AATD patients present with various A1-PI circulating levels and, therefore, are at different risks of developing emphysema. The
dotted line denotes the historical A1-PI threshold level (11 mM) below which patients are at an increased risk of developing emphysema.
AATD, Alpha-1 antitrypsin deficiency; A1-PI, alpha-1 proteinase inhibitor; N/D, not detectable.
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changes are seen in non-AATD, tobacco-related COPD. When
the changes noted above are discovered, A1-PI serum level
measurements should also be obtained and, in most cases, can
conﬁrm the diagnosis of AATD and allow further assessment of
disease severity. When interpreting serum levels, it is important
to note that A1-PI is an acute phase protein whose serum levels
can be artiﬁcially elevated during times of immune challenge (eg,
infection).1,20 As a result, patients with AATD may present with
normal or borderline A1-PI levels, despite additional evidence of
disease symptoms, and further testing should be considered
(Table III).
Genotyping and phenotyping allow for the identiﬁcation of
the most well-known AATD variants, providing some indication
of the severity of the deﬁciency. Phenotyping techniques such as
isoelectric focusing can be used to determine the well-known
serum A1-PI protein variant(s). Genotyping provides qualitative
information that can determine mutations in the SERPINA1
gene and identify the more common A1-PI deﬁciency alleles.Standard genotyping tests are allele speciﬁc and are usually run
with probes designed to target the Z and S alleles. If both of these
alleles are absent, the genotyping result is recorded as MM,
which means that nulls and other variants can be missed. In such
cases, phenotyping can be more informative, as isoelectric
focusing can allow for the identiﬁcation of rare proteins.
Furthermore, isoelectric focusing results may help to identify null
alleles when combined with other tests such as A1-PI serum level
measurements.21 However, this technique is expensive, time
consuming, and difﬁcult to interpret compared with A1-PI serum
level quantiﬁcation and genotyping. In addition to obtaining the
above tests in commercial laboratories, testing kits with varying
levels of sophistication are being offered free of charge by several
manufacturers of A1-PI replacement therapy preparations. Some
of these kits provide serum levels and genotyping, whereas others
are more comprehensive and also include C-reactive protein level
measurement, phenotyping, and, when needed, genetic analysis
using full gene sequencing, including promoter regions (next-
generation sequencing).
MONITORING THE PROGRESSION OF LUNG
DISEASE IN PATIENTS WITH AATD
Once a patient is diagnosed with AATD, the progression of
lung disease is traditionally monitored by spirometry using forced
expiratory volume in one second (FEV1) as an indicator of the
progression of lung airﬂow obstruction (Table III). Other
spirometric parameters (eg, diffusing capacity of carbon mon-
oxide) and records of number and severity of exacerbations are
also useful tools to measure lung disease progression and response
to therapy. CT densitometry enables the visualization and
monitoring of the progression of emphysema and has been used
in clinical trials as an alternative to spirometry. Lung CT has
been shown to be 2.5 times more sensitive than conventional
pulmonary function parameters and is recognized by the FDA as
TABLE II. American Thoracic Society/European Respiratory Society (ATS/ERS) criteria for screening and testing1
Recommended Should be discussed Not recommended
Diagnostic testing—symptomatic individuals
- Adults with persistent obstructive defects
on pulmonary function tests and COPD,
emphysema, or asthma (with incompletely
reversible airﬂow obstruction)
- Asymptomatic adults with evidence of
lung disease and smoking or occupational
exposure
- Newborns, children, or adults with unex-
plained liver disease
- Adults with necrotizing panniculitis
- Adults with persistent obstructive defects on pul-
monary function tests and bronchiectasis
- Adolescents with persistent obstructive pulmonary
dysfunction
- Asymptomatic adults with evidence of lung dis-
ease and no risk factors present for promoting
AATD-related lung disease
- Adults with multisystemic vasculitis (anti-PR-3-
positive vasculitis)
- Adults without persistent obstructive de-
fects on pulmonary function tests and
asthma (with completely reversible airﬂow
obstruction)
Predispositional testing—asymptomatic individuals
- Adults and adolescents with a sibling ho-
mozygous for an AATD deﬁciency allele
- Adults and adolescents with an offspring, a parent
or distant relative homozygous for and AATD
deﬁciency allele
- Adults and adolescents with a sibling, an offspring,
a parent or distant relative heterozygous for and
AATD deﬁciency allele
- Adults and adolescents with a family history of
obstructive lung disease or liver disease
- Neonatal testing
Carrier testing in the reproductive setting
- Adults and adolescents at high risk of having
AATD-related diseases
- Partners of individuals with AATD or carrier status
Screening
- Adults or adolescents in countries where AATD
prevalence and smoking rates are high (in the
presence of adequate counseling)
- Newborns and adolescents
- Healthy adults without increased risk of
AATD
- Smokers with normal spirometry
AATD, Alpha-1 antitrypsin deﬁciency; COPD, chronic obstructive pulmonary disease; PR-3, proteinase-3.
(Adapted with permission of the American Thoracic Society. Copyright  2015 American Thoracic Society. ATS/ERS statement. Am J Respir Crit Care Med 2003; 168:818-
900, ofﬁcial journal of the American Thoracic Society. This document was published in 2003. Certain aspects of this document may be out of date and caution should be used
when applying the information in clinical practice and other usages.)
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in research.22 It should be noted that its use in standard clinical
practice is less clearly deﬁned and current statements raise
practical issues. These include the availability of equipment, the
lack of expertise in analyzing and interpreting data, the cost, and
the radiation dose received by the patient.23BEYOND DIAGNOSIS—MONITORING AND
EFFECTIVE MANAGEMENT OF AATD
Early and correct diagnosis of AATD can enable appropriate
and effective management of the disease (Table IV). Current
management approaches mostly aim to alleviate AATD symp-
toms. Lifestyle modiﬁcations, such as smoking cessation,
pollutant avoidance, healthy diet, and regular exercise, can be
quickly implemented to maintain lung health and muscle mass
and help prevent further respiratory complications. In addition,
current pharmacological approaches involve the use of bron-
chodilators and anti-inﬂammatory therapy (inhaled corticoste-
roids) to relieve symptoms of airway obstruction and reduce
inﬂammation. Early and aggressive use of antibiotics when pa-
tients present with respiratory infections may reduce the poten-
tial for lung damage. Vaccines such as the inﬂuenza vaccine,
polysaccharide pneumococcal vaccine, and protein-conjugated
pneumococcal vaccine should be administered to reduce the
risk and severity of these infections. Oral corticosteroids shouldbe prescribed for patients with exacerbations. When appropriate,
supplemental or long-term oxygen is also indicated,1 and
consideration for transplant is important in progressive cases. For
ZZ individuals, liver transplant can be effective for both AATD-
related liver and lung disease. For other AATD variants and for
severe pulmonary disease in ZZ individuals, lung transplantation
should be considered. However, because the long-term prognosis
is poor post-lung transplant, appropriate therapies should be
given early and aggressively to help limit progressive lung disease.
Other approaches, including gene and stem cell therapies, are
currently being investigated; the development of these methods is
slowly progressing and might give rise to alternative treatments in
the future.24,25
Unlike lifestyle modiﬁcations or pharmacological management
of AATD symptoms, intravenous (IV) A1-PI administration is
the only therapy that directly addresses the underlying deﬁciency
of AATD. A1-PI preparations are usually administered weekly by
IV infusion at a dosage of 60 mg/kg of body weight. This dosage
is considered sufﬁcient to raise A1-PI serum levels above 11 mM,
a level historically considered to be the protective threshold, as
serum levels below this have been associated with an increased
risk of developing emphysema.1,20,26 Current commercially
available, FDA-approved, A1-PI products include Aralast NP and
GLASSIA (Baxter, Ill), Prolastin-C (Grifols, Barcelona, Spain),
and Zemaira (CSL Behring, Pa). The aim of augmentation
therapy is to slow the destruction of lung tissue and, until last
TABLE III. Current methods to diagnose and monitor alpha-1 antitrypsin deficiency30,31
Method(s) Aim Advantages Disadvantages
A1-PI quantitative testing
- Nephelometry;
radial immuno-
diffusion;
ELISA
- A1-PI blood concentration
assessment
- Widely available
- Readily automated
- Inexpensive
- Reliable
- Cannot identify heterozygotes
- A1-PI is an acute phase reactant and its
serum level can be artiﬁcially raised during
infection/stress
- Variation in daily A1-PI circulating levels
- Thresholds levels for each test vary and
patients can present with borderline levels
A1-PI qualitative testing
- Isoelectric
focusing
- Allele-speciﬁc
PCR
- Next-generation
sequencing
- A1-PI phenotyping
- A1-PI genotyping
- A1-PI sequencing
- Can characterize patients’ phenotype
- Can identify heterozygotes
- Semiautomated equipment available
- Inexpensive
- Conclusively identiﬁes common mutations
- Can conﬁrm genotyping results and detect
novel, rare, and multiple mutations
- Time consuming
- Experienced staff required to interpret results
- Interpretation of rare alleles is difﬁcult
- Does not detect null alleles
- Limited number of probes
- Rare mutations can be missed if not fol-
lowed by next-generation sequencing
- Expensive
- Limited availability
- Experienced staff required to interpret
results
Pulmonary function monitoring
- Screening
spirometry
- Full pulmonary
function tests
- Lung disease progression
monitoring
- Overall lung function assessment
- Degree of lung volume abnormality
and diffusion of CO assessment
- Widely available
- Quick and easy to perform
- Cost effective
- May suggest diagnosis
- Can conﬁrm obstruction
- Determines degree of diffusion abnormality
- Allows assessment of total lung volume
and residual volume
- Day-to-day variability and wide normal
ranges
- Limited availability
- Pulmonary qualitative monitoring
- CT scanning - To assess pulmonary densitometry - Provides a sensitive and accurate assess-
ment of lung density
- Reliably indicates lung disease progression
- Expensive
- Limited availability
- Experienced staff required
A1-PI, Alpha-1 proteinase inhibitor; CO, carbon monoxide; CT, computed tomography; PCR, polymerase chain reaction.
TABLE IV. Current available therapeutic approaches to manage alpha-1 antitrypsin deficiency
Therapy Aims
Lifestyle modiﬁcations
- Smoking cessation
- Environmental risks avoidance
- Nutritional follow-up
- Pulmonary rehabilitation
- Exercise
- Preserve lung health
- Improve the patient’s quality of life
Asthma and COPD pharmacological management
- Inhaled bronchodilators
- Inhaled steroids
- Antibiotics
- Oral corticosteroids
- Oxygen therapy
- Inﬂuenza vaccine
- Pneumococcal vaccine both conjugate and polysaccharide as per guidelines
- Improve symptoms of airway obstruction
- Relieve/slow down lung tissue destruction
- Prevent infections
Augmentation therapy
- Intravenous puriﬁed A1-PI - Reduce the rate of lung tissue destruction
- Slow the progression of respiratory decline
- Delay time to terminal respiratory event
A1-PI, Alpha-1 proteinase inhibitor; COPD, chronic obstructive pulmonary disease.
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studies and 2 small randomized controlled pilot trials
(RCTs).27,28 These pilot RCTs showed no difference in the
decline of FEV1 between treated and control patients; however, a
trend was observed for the reduction of lung density decline in
the treatment group. These observations called for further in-
vestigations. The results of the recently completed Randomized,
placebo-controlled trial in Alpha-1 Proteinase Inhibitor Deﬁ-
ciency (RAPID, NCT00261833), which followed 180 patients
(93 treated and 87 placebo) over 2 years, provide evidence that
IV A1-PI augmentation therapy signiﬁcantly slows the progres-
sion of emphysema in individuals with severe AATD. Results
from this trial indicate that, compared with placebo, A1-PI
therapy delays time to terminal respiratory event (lung trans-
plantation or death) and reduces overall progression of emphy-
sema in patients with AATD and emphysema.29
CONCLUSIONS
As allergists and/or immunologists, we see numerous patients
with asthma, in particular, patients with severe asthma and
abnormal FEV1 thought to be secondary to remodeling. How-
ever, another potential cause of ﬁxed obstructive airway disease is
AATD, and screening patients for AATD could identify some of
the 90% of individuals with AATD who are not yet diagnosed,15
which enables the implementation of appropriate care. The aim
is that in the future the diagnosis of AATD will be made by the
allergist and/or immunologist early in the disease, and appro-
priate therapy initiated to prevent progression of the lung dam-
age. Patients with atypical asthma, with ﬁxed airway obstruction
or a family history of early COPD or unexplained COPD,
should be screened for AATD. This should enable early diagnosis
and effective management of AATD to decrease morbidity and
premature mortality associated with this condition.
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